Secondary prophylaxis of an acute coronary syndrome during rituximab infusion

Med Clin (Barc). 2020 Jan 24;154(2):69-70. doi: 10.1016/j.medcli.2019.04.007. Epub 2019 Jun 6.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acute Coronary Syndrome / chemically induced
  • Acute Coronary Syndrome / prevention & control*
  • Aged
  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cardiovascular Agents / therapeutic use
  • Clopidogrel / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Diltiazem / therapeutic use
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Lymphoma, Follicular / drug therapy*
  • Lymphoma, Follicular / pathology
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prednisone / administration & dosage
  • Rituximab / administration & dosage
  • Rituximab / adverse effects*
  • Secondary Prevention*
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents, Immunological
  • Cardiovascular Agents
  • Platelet Aggregation Inhibitors
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Clopidogrel
  • Diltiazem
  • Prednisone

Supplementary concepts

  • CHOP protocol